BTIG Reaffirms Buy Rating for Monopar Therapeutics (MNPR) Following Strong Phase 3 Wilson Disease Data
Tweet Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $104.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented, "MNPR ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
